Core Insights - Evernorth, the health services division of The Cigna Group, has launched a new pharmacy benefit offering that makes weight loss medications WEGOVY® and ZEPBOUND® more accessible to patients, with a maximum monthly cost of $200 [1][6]. Patient Benefits - Patients can save up to $3,600 annually compared to direct-to-consumer manufacturer programs [6][7]. - Monthly copays for GLP-1 weight loss medications will be capped at $200, which will count towards the patient's annual deductible [7]. - The new offering ensures access to FDA-approved medications with robust safety checks to minimize adverse drug interactions [7]. - The prior authorization process will be simplified and automated for quicker access to medications [7]. - Patients have the option to choose from a wide network of local retail pharmacies or home delivery through Evernorth's EnGuide Pharmacy [7]. Employer and Health Plan Sponsor Benefits - Health plan sponsors will experience a significant reduction in the net cost per prescription for GLP-1 medications [7]. - The initiative addresses the growing demand for FDA-approved weight loss medications while ensuring clinical safety for patients [6][7]. - Evernorth's extensive suite of GLP-1 solutions provides health plan sponsors with options to ensure patients have access to the most suitable medications without compromising affordability [7]. Additional Information - EncircleRx has saved health plans $200 million since 2024, with over 9 million enrolled lives [8]. - EnReachRx is a patient support clinical model designed for dispensing GLP-1 prescription medications [8].